Low-dose milrinone to prevent heart instability after PDA closure in extremely preterm babies
1/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) – CCC
This gives very low doses of the heart medicine milrinone to extremely preterm infants around the time their patent ductus arteriosus is closed to try to prevent unstable blood pressure and breathing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11331048 on NIH RePORTER |
What this research studies
If your baby is an extremely preterm infant who needs closure of a patent ductus arteriosus (PDA), this project will give low-dose milrinone around the time of the procedure and follow how the baby does afterward. The research is organized through a clinical coordinating center at the University of Iowa and will enroll babies treated at participating neonatal centers. Doctors will track heart and lung stability after PDA closure and compare outcomes between those who receive milrinone and those who do not. The goal is to find a safe way to reduce the common post-procedure instability that can affect breathing and development.
Who could benefit from this research
Good fit: Extremely preterm infants (for example, very low birth weight or born <1000 g) who are scheduled to undergo interventional closure of a patent ductus arteriosus are the ideal candidates.
Not a fit: Infants who do not require PDA closure, older children or adults, or babies with medical reasons that make milrinone unsafe are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this could lower the risk of post-ligation cardiac syndrome and related respiratory and long-term developmental problems after PDA closure in extremely preterm infants.
How similar studies have performed: Preliminary and observational data suggest early milrinone can reduce post-procedural instability, but larger controlled trials are limited and this effort aims to provide stronger evidence.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Mcnamara, Patrick J — University of Iowa
- Study coordinator: Mcnamara, Patrick J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.